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Editor’s key points
† This study investigated
which published
pharmacokinetic (PK) model
best describes the time
course of alfentanil plasma
concentration after bolus
administration and during
continuous infusion.
† Out of the eight models
tested, PK parameters by
Scott and by Maitre were
equally valid when alfentanil
was given as repeated
boluses.
† When given as infusion the
Maitre parameters were less
accurate and subject to a
significant bias.
† Simultaneously
administered hypnotics
during alfentanil continuous
infusion might affect the PK
time course.
Background. In open TCI and anaesthesia display systems, the choice of
pharmacokinetic (PK) parameter sets of opioids is clinically relevant. Accuracy and
bias of the PK models may be affected by administration mode and the co-
administered hypnotic drug. We retrospectively evaluated the performance of eight
PK parameter sets for alfentanil in two data sets (infusion and bolus application).
Methods. With the dosing history from two studies in orthopaedic patients
anaesthetized with propofol or inhalation anaesthetics the alfentanil plasma
concentration over time was calculated with eight PK parameter sets. Median
absolute performance error (MDAPE), log accuracy, median performance error
(MDPE), log bias, Wobble, and Divergence were computed. Mann–Whitney rank test
with Bonferroni correction was used for comparison between bolus and infusion
data, repeated measures analysis of variance on ranks was used for comparison
among parameter sets.
Results. The parameters by Scott (original and weight adjusted) and Fragen had a
MDAPE ≤30% and a median log accuracy ,0.15 independent of the administration
mode, while MDPE was within +20% and log bias nearly within +0.1, respectively.
The sets by Maitre and Lemmens were within these limits only in the bolus data. All
other parameter sets were outside these limits.
Conclusions. In healthy orthopaedic patients, the PK parameters by Scott and by Maitre
were equally valid when alfentanil was given as repeated boluses. When given as
infusion, the Maitre parameters were less accurate and subject to a significant bias.
We cannot exclude that the difference between bolus and infusion is partially
because of the different hypnotics used.
Keywords: drug delivery, bolus, drug delivery, infusion; equipment, infusion systems;
pharmacokinetics, alfentanil
Accepted for publication: 25 January 2013
With the introduction of open target controlled infusion (TCI)
systems, not only propofol but also opioids became available
for application as TCI in clinical practice. Although remifenta-
nil is most popular, also alfentanil and sufentanil parameters
are offered by some manufacturers. The optimal PK para-
meters for propofol are still a matter of some debate,1 – 3
whereas the parameter set for remifentanil reported by
Minto and colleagues4 is unchallenged except for a change
of the lean body mass formula in the morbidly obese.5
Because of its PK profile with fast onset and acceptable
offset characteristics, alfentanil might also be an interesting
drug for TCI. The slower off-set compared with remifentanil
may offer some advantage in transition from intraoperative
to postoperative analgesia.
Beside open TCI, also anaesthetic drug display systems re-
cently became available.6 7 They present predicted drug con-
centrations of i.v. anaesthetics and measured concentrations
of inhalation anaesthetics and compute the combined an-
aesthetic potency of the applied drugs using interaction
models.8 – 10 The selection of appropriate models is essential
for the performance of TCI and anaesthesia display systems.
In anaesthesia display systems, also bolus application of i.v.
drugs (especially opioids) is possible. An appropriate PK par-
ameter set should therefore not be affected by the mode of
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application. According to Schu¨ttler and colleagues,11 the PK
parameters for propofol were significantly affected by the
mode of administration.
The pharmacokinetics and -dynamics (PKPD) of alfentanil
and its interaction with propofol has been thoroughly inves-
tigated in the 1980s and 1990s.12 – 23
An open TCI system to administer alfentanil is currently
available only from one manufacturer using the PK param-
eter set by Maitre18 which is based on data from bolus ad-
ministration collected by several investigators.12 14 24 19 The
parameter set was later validated in 19 surgical patients
anaesthetized with nitrous oxide and alfentanil (boluses
and variable maintenance infusions).25
Raemer and colleagues26 found a bias and an inaccuracy of
.50% when using the Maitre18 parameters to drive a TCI
pump in healthy young women and elderly men, whereas
bias and inaccuracy was only21 and 17% with the Scott para-
meters.20 They suspected different clearances and adminis-
tration modes of alfentanil (bolus vs infusion) as possible
explanation for this difference. Barvais and colleagues27 admi-
nistered alfentanil as infusion with different rates, took venous
blood samples and developed a population and individual two-
compartment models for alfentanil kinetics. Compared with
infusion data, they found a higher elimination clearance and
a higher performance error in data where a large bolus was
rapidly applied. Mertens and colleagues28 showed that propo-
fol significantly reduces the clearance of alfentanil especially
during induction.
Masui and colleagues3 have compared different PKPD
models for propofol using bolus, infusion and TCI data. A
comparable study is not available for opioids.
We postulate that an optimal parameter set should not be
affected by the mode of drug application (bolus or infusion)
and should allow predictions of the plasma concentration
with a performance error of ≤30%29 and a bias within
+20%.3 For safety reasons overprediction of the concentration
rather than underprediction would be preferable for an opioid.30
The aim of this study was to compare the performance of
previously published PK models for alfentanil and to deter-
mine which of the different models is most appropriate for
use in TCI and anaesthesia drug display systems according
to previously defined criteria. We used two data sets from
the department of anaesthesia of the Bern University Hos-
pital. Alfentanil was administered by TCI31 and as repeated
single bolus doses (unpublished data), respectively.
Methods
For this investigation, we retrospectively analysed the mea-
sured alfentanil plasma concentration and recorded dosing
histories of two previously performed clinical studies.31
In the first study31 (data set I, ‘I’ for infusion data), 30
patients undergoing orthopaedic surgery were randomly
allocated to anaesthesia with 70 vol.% of xenon or 70
vol.% of nitrous oxide plus 2 vol.% of desflurane. Alfentanil
was administered by TCI (Stanpump programme, S.L.
Shafer, MD., Palo Alto, CA, USA) using the parameter set by
Shafer (as integrated in Stanpump) with target concentra-
tions between 5 and 400 ng ml21. Arterial blood samples
were obtained at baseline, before and after skin incision,
before and after each change of the target concentration,
after pump stop, and hourly in the recovery room for 3 h.
In the second study (unpublished, data set B, ‘B’ for bolus
data), 40 patients undergoing orthopaedic surgery were anaes-
thetized with propofol TCI (plasma target mode) using the par-
ameter set by Schnider and colleagues32 and alfentanil
administered as i.v. boli of 0.5–1.0 mg using an ASENA GH infu-
sion pump (Carefusion Corporation, San Diego, CA, USA) which
was connected to a laptop computer for recording of the
dosing history. Arterial blood samples were obtained at base-
line, before and after tracheal intubation, after skin incision, at
the end of surgery, before pump stop, and after extubation.
For both studies approval from the ethics committee had
been obtained and the patients gave their written informed
consent (reference code: KEK Bern 156-97 and KEK Bern
82-06, respectively). In all patients, the arterial blood
samples were centrifuged immediately after the end of the
case and the supernatant was stored at 2268C. The plasma
concentrations were measured by gas chromatography mass
spectrometry with a lower detection limit of 2 ng ml21.33
The alfentanil dosing histories from the two studies (data set I
and B) were used as input to calculate predicted plasma concen-
trations over time based on eight different PK parameter sets
using the PKPD Tools for Excel by Minto and Schnider (PKPD
Tools is freely available on the internet at www.pkpdtools.
com). The following parameter sets were compared: Scott and
Stanski,20 Scott and Stanski weight adjusted (as integrated in
Stanpump), Maitre,18 Shafer (as integrated in Stanpump),
Hudson,16 Mertens,28 Fragen,15 and Lemmens17 (Tables 1–3).
For every blood sample, the measured and the predicted
alfentanil plasma concentrations were used to calculate
the performance error of the different models according to
Varvel and colleagues30 (equation 1).
PEij =
Cmij − Cpij
Cpij
, (1)
where PE¼performance error (%), Cm¼measured concen-
tration, Cp¼predicted concentration, i¼patient number and
j¼blood sample number in patient i.
The median absolute performance error (MDAPEi) and the
median performance error (MDPEi) were determined for each
patient according to the following equations 2 and 3:30
MDAPEi(accuracy) = Median{|PEij|, j = 1, ...,Ni}, (2)
MDPEi(bias) = Median{PEij, j = 1, ...,Ni}, (3)
where MDAPEi represents the accuracy and MDPEi the bias of
patient i with j¼1,. . .,Ni blood samples. Population estimates
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were calculated according to equations 4 and 5 (two-stage
approach).30
MDAPE (accuracy) = Median{MDAPEi, i = 1, ...,M}, (4)
MDPE (bias) = Median {MDPEi, i = 1, ...,M}, (5)
where MDAPE represents the population accuracy and MDPE
represents the population bias of i¼1,. . ., M patients.
Wobble representing the variation of the performance
error around MDPE and Divergence representing the
expected time related changes in performance were calcu-
lated according to the following equations 6 and 7:
Wobblei = Median(|PEij − MDPEi|), (6)
Divergencei = 60 ×
∑ |PEij| × tij − (
∑ |PEij|) × (
∑
tij)/Ni
∑ (tij)2 − (
∑
tij)2/Ni
, (7)
where Wobblei and Divergencei are the estimates for patient i
with j¼1,. . .,Ni blood samples and tij is the time in min that
the corresponding PEij was determined. Population estimates
were calculated similar to those of MDAPE and MDPE (equa-
tions 4 and 5).
For comparison, the recently proposed logarithmic indices
for accuracy and bias described by Masui and colleagues3
were calculated as well using the following equations 8 and 9:
Accuracyi = Median {|log(Cmij/Cpij)|, j = 1, ...,Ni}, (8)
Biasi = Median{log(Cmij/Cpij), j = 1, ...,Ni}, (9)
where Accuracyi and Biasi are the estimates for patient i with
j¼1,. . .,Ni blood samples. Population estimates were calcu-
lated by analogy with the population estimates of MDAPE
and MDPE (equations 4 and 5).
We defined an optimal parameter set for use in TCI and
display systems as follows: It should be unaffected by the
mode of administration (bolus vs infusion), the MDAPE
(accuracy) should be ≤30%29 and the MDPE (bias) should
be within +20%.3
Acceptable ranges for the logarithmic accuracy and bias
indices had been derived from MDAPE and MDPE with
values of ,0.1–0.15 for accuracy and of 20.1 to 0.1 for
bias, respectively.3
Table 1 Characteristics of the study populations in the different PK studies on alfentanil. Data are total count of subjects, blood samples, males,
and females. Weight and height are mean [standard deviation (SD)], age is mean (range). I, infusion; B, bolus; n.a., not available; NA, not
applicable; (refers to single bolus application studies). The duration of the alfentanil infusion is presented as number, range or mean (SD). HALO,
halothane; ENF, enflurane; SUF, sufentanil; Thio, thiopental; ETO, etomidate; Xe, xenon; DES, desflurane; ISO, isoflurane. From the parameters by
Shafer (as implemented in the Stanpump software) no data on the study population are available
Scott20 Fragen15 Maitre18 Lemmens17 Mertens28 Hudson16 Current study
infusion
Current
study bolus
Number of subjects 17 5 45 36 8 11 30 40
Number of blood
samples
680 80 614 1000 342 253 649 201
Type of blood
samples
Arterial Venous Arterial and
venous
Arterial and
venous
Venous Arterial Arterial Arterial
Sex (M/F) 17/0 2/3 14/31 15/21 8/0 9/2 16/14 24/16
Age (yr) 52 (20–89) 39 (29–48) 47 (19–91) 53 (24–79) 24 (n.a.) 64 (51–76) 33 (18–54) 40 (18–81)
Weight (kg) n.a. 72 (9) 65 (6) 74 (12) 74 (6) 75 (14) 71 (14) 74 (11)
Height (cm) n.a. n.a. 165 (7) n.a. 182 (7) n.a. 172 (9) 172 (9)
Application of drug I Single B and I Single B I I Single B I Repeated B
Max. plasma
concentration (ng
ml21)
.1000 900 .1000 1000 ,150 2000 500 1000
Duration of
alfentanil
administration
(min)
3 (2) 60 NA 45–240 60 NA 195 (62) 264 (72)
Co-administered
anaesthetics
Thio, ENF,
N2O
Thio, ENF,
N2O
Thio, N2O
ETO, N2O,
HALO
Thio, N2O, ENF
or HALO
N2O, SUF Propofol N2O, ISO Xe 70% or
N2O 70%/DES
2%
Propofol TCI
Type of surgery Elective
surgery with
minimal
blood loss
Elective
surgery .1 h
and blood
loss ,500 ml
Miscellaneous Lower
abdominal
Volunteers Infrarenal
aortic
Orthopaedic Orthopaedic
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Table 2 PK parameter sets. Parameters of the studies as published in the literature. The models are described either by their volumes and
clearances or V1 and micro rate constants, which are convertible. Weight in kg, height in cm, body surface area (BSA) according to the Du Bois
formula38: BSA¼(weight 0.425 × height 0.725) × 0.007184. M, men; F, female
Scott20 Fragen15 Shafer Maitre18 Lemmens17 Mertens28 Hudson16
V1 (litre) 2.185
weight adjusted:
2.185/70 × weight
0.130 ×
weight
0.825×
BSA
M: 0.111 × weight
F: 0.128 × weight
M: 4.106
F: age≤50:
4.174
F: age.50:
3.566
0.115 ×
weight
0.044 ×
weight
V2 (litre) 0.220 ×
weight
0.208 ×
weight
0.189 ×
weight
V3 (litre) 0.136 ×
weight
0.399 ×
weight
Cl1 (litre
min21)
0.195 Age≤40: 0.356
Age.40
0.3562[0.00269 ×
(age240)]
0.00564 ×
weight
0.0064 ×
weight
Cl2 (litre
min21)
0.0738 ×
weight
0.0138 ×
weight
Cl3 (litre
min21)
0.00248 ×
weight
0.0021 ×
weight
K10
(min21)
0.02767 0.0748 M: 0.0679
F: age≤50:
0.1031
F: age.50:
0.0717
K12
(min21)
0.656 0.052167 0.515 0.104 M: 0.2818
F: age≤50:
0.3475
F: age.50:
0.1810
K13
(min21)
0.113 0.231 0.017 M: 0.0806
F: age≤50:
0.1298
F: age.50:
0.1352
K21
(min21)
0.214 0.03033 0.142 0.0673 M: 0.1219
F: 0.1580
K31
(min21)
0.017 0.0185 Age≤40
0.0126
Age.40
0.01262 [0.000113 ×
(age2 40)]
M: 0.0150
F: age≤50:
0.0170
F: age.50:
0.0143
Table 3 PK parameters calculated for a standard patient. Volumes (litres) and clearances (litre min21) of the PK parameter sets calculated for a
70 kg, 170 cm and 30-year-old male
Scott20 Fragen15 Shafer Maitre18 Lemmens17 Mertens28 Hudson16
V1 2.19 9.1 1.5 7.77 4.11 8.05 3.08
V2 6.7 15.4 5.44 12.01 9.49 14.56 13.23
V3 14.52 18.73 10.48 22.06 9.52 27.93
Cl1 0.195 0.252 0.112 0.356 0.279 0.395 0.448
Cl2 1.433 0.467 0.772 0.808 1.157 5.166 0.966
Cl3 0.247 0.346 0.132 0.331 0.174 0.147
BJA Sigmond et al.
200
Statistics
MDAPE, MDPE, Wobble, and Divergence according to Varvel
and colleagues30 and logarithmic accuracy and bias accord-
ing to Masui and colleagues3 of the different parameter sets
were compared. Mann–Whitney rank test with Bonferroni
correction was used for comparison between the infusion
and bolus application data. Repeated measures analysis of
variance (ANOVA) on ranks with Tukey test was used for mul-
tiple pair-wise comparisons between the parameter sets for
MDAPE, log accuracy and Wobble. For MDPE, log bias, and Di-
vergence, the parameter set with an optimal bias nearest to
zero was selected as control. Dunnett’s test was used to
compare the other sets with control (Sigmastat 3.5, Systat
Software GmbH, Erkrath Germany). Using a statistical test
with control for signed indices (MDPE, log bias and Diver-
gence) allowed identifying sets differing significantly from
the defined optimal range around zero instead of identifying
significant differences between sets from low negative to
high positive values. Significance was accepted at a P-value
of ,0.05 (with Bonferroni correction for eight comparisons
yields a P-value of ,0.006).
Results
The data from 30 patients (infusion) and 40 patients (bolus)
were included. The characteristics of the study populations
are presented in Table 1 (last 2 columns). The mean
(range) age of the patients was 33 (18–54) in Group I and
40 (51–76) in Group B (P¼0.035). The median (inter-quartile
range) blood loss in Group I and B was 500 (400–760) and
400 (210–700) ml (P¼0.09), the duration of the alfentanil
administration was 264 (72) and 195 (62) min, respectively
(P,0.001). The median (inter-quartile range) of the predicted
plasma alfentanil concentration throughout the study was
72 (54–104) ng ml21 in Group I and 143 (113–175) ng
ml21 in Group B (P,0.001). Twenty-six of 30 patients in
Group I and 20 of 40 in Group B were ASA physical status I,
the remainder was ASA II (P¼0.003). The time course of
the plasma concentrations in two typical patients of our
study groups is presented in Figure 1.
A total of 850 blood samples were analysed, 649 in the in-
fusion and 201 in the bolus study, respectively. All blood
samples could be included in the analysis.
MDAPE and log accuracy
The median MDAPE and log accuracy in both populations was
within the limits of acceptance with the parameter sets by
Scott,20 Fragen,15 and Scott weight adjusted, whereas it
was outside with the others (Fig. 2).
In the infusion data (green boxes in Fig. 2), the MDAPE
with the Scott parameters was significantly lower than with
the parameters by Hudson,16 Mertens,28 Lemmens,17 and
Shafer (P,0.05). MDAPE values were 22.3% (Scott),20 26.5%
(Fragen),15 26.5% (Scott weight adjusted), and 41%
(Maitre).18 The log accuracy was significantly lower compared
with Hudson,16 Lemmens,17 and Shafer (P,0.05).
In the bolus data (orange boxes in Fig. 2), the MDAPE and
log accuracy of the parameter sets by Scott,20 Fragen,15 Scott
weight adjusted, Maitre,18 and Lemmens17 were similar,
whereas those of Shafer and Hudson16 were significantly
higher. MDAPE values were 30.2% (Scott),20 26% (Fragen),15
29.3 (Scott weight adjusted) and 24.1% (Maitre).18
In the parameter sets by Maitre18 and Lemmens,17 the
MDAPE was higher when alfentanil was administered as infu-
sion compared with bolus administration; whereas in the log ac-
curacy this difference was significant with the parameters by
Lemmens17 (P,0.003). This was reflected by the multiple pair-
wise comparisons between the different parameter sets, which
yielded different results when alfentanil was administered as
multiple boluses or as infusion (as mentioned above).
None of the performance indices inside the Group I were
affected by the different co-administered hypnotic drugs
(desflurane plus nitrous oxide or xenon, P≥0.361).
The detailed results of the multiple pair-wise comparisons
of all the parameter sets are presented in Figure 2.
MDPE and log bias
The parameter set by Fragen15 was selected as control
because MDPE and log bias were optimally within the accept-
able range (Fig. 3). The median MDPE and log bias in the
study populations were within or very close to the acceptable
limits (+20% or +0.1) with the parameters by Fragen,15
Scott,20 and Scott weight adjusted, whereas the others
were all significantly different from control (Fig. 3).
In both data sets MDPE and log bias of the parameter sets of
Scott,20 Scott weight adjusted and Shafer showed tendency to
overpredict whereas those of Maitre,18 Hudson,16 and
Mertens28 showed tendency to underpredict the measured
concentration (Fig. 3). MDPE values were 218.4% (Scott),20
26% (Fragen),15 224% (Scott weight adjusted) and 39.4%
(Maitre)18 with the infusion data and 230% (Scott),20
218.3% (Fragen),15 224.6% (Scott weight adjusted) and
0.6% (Maitre)18 with the bolus data. As MDAPE and log accur-
acy also MDPE and log bias were affected by the mode of
administration (infusion or bolus) with the parameters by
Maitre,18 but not Lemmens (P,0.001).17 None of the perform-
ance indices inside the Group I were affected by the different
co-administered hypnotic drugs (desflurane plus nitrous
oxide or xenon, P≥0.263). The detailed results of the multiple
pair-wise comparisons of the different parameter sets are pre-
sented in Figure 3.
Wobble and divergence
In both populations, the variation of the PE around the MDPE
(Wobble) in the Scott parameters (weight adjusted or not)
was lower compared with those by Hudson,16 Mertens,28
Lemmens,17 and Maitre.18 The Wobble was also affected by
the mode of administration with the parameters by Scott,20
Fragen,15 Maitre,18 and Mertens.28 Further details are
reported in Figure 4.
In both populations, the Divergence was+5% or less in the
parameters by Scott (weight adjusted or not), Fragen,15
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Maitre,18 Lemmens,17 and Mertens.28 In the infusion group,
the median (inter-quartile range) of the Divergence (% h21)
for the Hudson16 and Shafer parameters was 12 (0.8, 45) and
9 (7, 12), respectively. In bolus application, the Divergence
values were 18 (2, 31) and 7 (5, 10), respectively (Fig. 4).
Discussion
The previously defined criteria for an optimal parameter set
(being unaffected by mode of administration, MDAPE (accur-
acy) ≤30% and MDPE (bias) within (+20%) were met by the
Scott20 (original and weight adjusted version) and the
Fragen15 parameters. The Scott20 parameters overpredicted
the measured concentration whereas those by Fragen15 per-
formed with almost no bias. Weight did not affect the PE of
the Scott20 parameters in our data set, which means that
weight adjustment did not worsen the PE. Because all para-
meters used for TCI are at least weight adjusted we consider
it reasonable to apply weight adjustment for alfentanil too.
The Fragen parameters15 represent a two-compartment
model developed with data from five patients (venous
blood samples) and belong to the earliest published para-
meters of alfentanil. Despite the limited database their per-
formance was similar to the Scott parameters. Because the
300
250
200
150
100
50
0
0 100 200 300 400 500
Time (min)
Al
fe
n
ta
ni
l C
p 
(ng
 m
l–1
)
300A
B
250
200
150
100
50
0
0 100 200 300 400 500
Time (min)
Al
fe
n
ta
ni
l C
p 
(ng
 m
l–1
)
Scott weight adjusted
Maitre
Measured concentrations
Scott weight adjusted
Maitre
Measured concentrations
Fig 1 Alfentanil plasma concentrations in the two study populations. Predicted and measured alfentanil plasma concentrations (Cp axis)
against time of two typical patients of our study populations. A, infusion group; B, repeated bolus group. The predicted plasma concentrations
according to Scott, weight adjusted (blue lines) and Maitre (red lines). Measured plasma concentrations are represented by green circles.
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study population was very small the data did not allow esti-
mating the parameters for the third compartment.
The Maitre parameter set25 was developed from pooled
bolus data from Bovill,12 Camu,14 Helmers,24 and Schu¨ttler19
forming a representative study population with a large
number of blood samples allowing to estimate the effect of
age, sex and weight as covariates. With our data from
repeated bolus application it performed as good as Scott20
but was significantly inferior with the infusion data. The
reason may be the higher elimination clearance of the
Maitre parameters.27 A comparable performance with
similar differences regarding bolus and infusion application
could be observed with the parameter set by Lemmens.17
All other parameter sets did not meet our criteria and
cannot be recommended for use in TCI or anaesthesia
display systems.
Contrary to Scott20 and Fragen15 the Maitre,25 and
Lemmens17 parameters underpedicted the alfentanil con-
centration. From a safety point-of-view this might be a
further disadvantage for clinical practice. If the concentra-
tion of a drug is underpredicted a TCI will administer more
than if it is overpredicted. An inadequate analgesia is clinic-
ally detectable (e.g. by haemodynamic responses to surgical
stimuli) and can be easily corrected.30 Conversely, an over-
dose of analgesic drugs is more difficult to detect clinically.
Underdosing is therefore preferable in order to avoid
delayed recovery, opioid induced hyperalgesia, or post-
operative respiratory depression.30
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Fig 2 MDAPE and log accuracy of alfentanil concentrations: infusion and bolus data. MDAPE and log accuracy distribution as box-plot with
median and percentiles. Green boxes, infusion data; orange boxes, bolus data. Error bars indicate the 10th/90th percentiles, black circles rep-
resent 5th/95th percentiles. Scott-WA, Scott weight adjusted version of the Scott parameters (as implemented in Stanpump). Dashed lines
represent the borders of acceptable prediction errors (≤30% and ,0.1–0.15). *Significant differences between infusion and bolus administra-
tion (Mann–Whitney rank test and Bonferroni P,0.006). The numbers above the boxes refer to the repeated measures ANOVA on ranks with
multiple pair-wise comparisons among the different parameter sets (Tukey test): (1) P,0.05 compared with Hudson, Lemmens, Shafer,
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Hudson and Shafer; (5) P,0.05 compared with Shafer. Where no reference is indicated the performance error is not significantly different
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Mertens and colleagues28 described the PK interaction
between alfentanil and propofol in healthy volunteers. A pro-
pofol Cp of 1.5 mg ml21 reduced the Clearances 1, 2 and 3 by
15, 300 and 50%, respectively, which was attributed to a
reduced hepatic blood flow because of the propofol
induced vasodilatation. Because propofol and alfentanil
both are bound to lung tissue (first pass effect) the alfentanil
concentrations after the initial bolus of alfentanil were higher
than expected in the presence of propofol. The population
studied by Mertens and colleagues28 is not representative
for the patient population undergoing surgery. This may
explain why the performance of the Mertens parameter set
was inferior to others even in our data set where propofol
was co-administered.
The intra-individual variation of the prediction error
(Wobble) was higher when alfentanil was administered as
boluses in most of the parameter sets. In the bolus data, it
was lower in the Scott20 than in the Maitre25 parameters.
The variation of the performance error over time (Diver-
gence) was highest in the Hudson16 parameters, probably
because they were determined in cardiovascular high risk
patients, which is a different population compared with our
patients. The elimination clearance estimated by Hudson16
is higher compared with parameter sets that were more
stable over time. The lowest Divergence had the Scott20 para-
meters, expressing the higher ability to produce stable
plasma concentrations of this set compared with other
sets, which can be seen as advantage for titration of anal-
gesia in clinical use. Fragen’s15 negative Divergence values
in both data sets mean that the performance error was
higher at the beginning of the infusion.
Our results obtained in 70 patients with a total of 850
blood samples are consistent with those of Barvais and col-
leagues27 obtained in eight volunteers and with those of
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Fig 3 MDPE and log bias of alfentanil concentrations: infusion and bolus data. MDPE and log bias distribution as box-plot with median and
percentiles. Green boxes, infusion data; orange boxes, bolus data. Error bars represent 10th/90th percentiles, black circles represent 5th/
95th percentiles. Scott-WA, Scott weight adjusted version of the Scott parameters (as implemented in Stanpump). Dashed lines represent
the range of acceptable prediction errors (between +20% and +0.1). *Significant differences between infusion and bolus administration
(Mann–Whitney rank test and Bonferroni P,0.006). #Significant differences to control (repeated measures ANOVA on ranks with multiple pair-
wise comparisons of the different parameter sets vs Fragen as control, Dunnett’s test).
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Raemer and colleagues26 obtained in 29 healthy women and
22 older men. They also confirm that the application mode
may affect the prediction error of PK parameters.26 27 In an
earlier study on 25 patients where alfentanil was adminis-
tered as TCI during surgery and for postoperative pain
control34 the MDAPE of the Scott parameters20 was similar
to the parameters by Lemmens17 and Maitre.18 The blood
samples in that study34 were obtained only in the
postoperative study period where the subjects were closer
to a PK pseudo-steady state. In the late phase of drug
administration, the inaccuracy related to the volume of the
central compartment (volume 1) which is 3-fold larger in
the Maitre set, is less important than at the beginning. This
may explain the different result compared with previous
studies26 27 and our data.
Perus and colleagues35 recently evaluated the predictive
performance of the Maitre25 and the Scott20 parameters in
10 obese and 6 non-obese women anaesthetized with des-
flurane after a propofol induction. During drug infusion, the
Scott parameters were superior to the Maitre parameters in
the non-obese controls, while they were similar in the
obese. Conversely, the decay after infusion stop was better
predicted by the Maitre parameters in both patient groups.
As our study populations were non-obese, these results are
consistent with ours.
None of the investigated parameter sets is perfect. Par-
ticularly, the initial phase of drug administration and the ter-
minal phase of drug elimination are not well predicted. Most
authors of the previous studies concluded that further
studies are necessary. Because of the high costs and the
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Fig 4 Variation of the performance error: Wobble and Divergence. Median intra-individual variation of the performance error around the MDPE
(Wobble) and median intra-individual variation of the performance error over time (Divergence) as box-plots with median and percentiles.
Green boxes, infusion data; orange boxes, bolus data. Error bars represent 10th/90th percentiles, black circles represent 5th/95th percentiles.
Scott-WA, Scott weight adjusted version of the Scott parameters (as implemented in Stanpump). Wobble: repeated measures ANOVA on ranks
with multiple pair-wise comparisons among the different parameter sets (Tukey test): (1) P,0.05 compared with Hudson, Mertens, Lemmens,
and Maitre; (2) P,0.05 compared with Hudson, Mertens, Lemmens, Shafer, and Maitre; (3) P,0.05 compared with Hudson, Mertens, and
Lemmens; (4) P,0.05 compared with Hudson. *Significant differences between infusion and bolus administration (Mann–Whitney rank test
and Bonferroni correction, P,0.006). Where no reference is indicated the performance error is not significantly different from any other.
Divergence: #significant differences to control (repeated measures ANOVA on ranks with multiple pair-wise comparisons of the different param-
eter sets vs Fragen as control, Dunnett’s test).
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lack of clinical relevance in the absence of open TCI systems
or anaesthesia display systems in the past, they have not
been performed yet. It is even uncertain if larger studies
would yield better parameter sets at all. Some arguments
supporting this statement can be found in the paper by
Schnider and colleagues32 reporting the propofol PK param-
eter set. Beside developing a new PKPD parameter set the
purpose of the study was to prove that adding ethylenedia-
minetetraacetate (EDTA) to the previous propofol formula
does not change PKs. Therefore, each patient was examined
twice, once with and once without EDTA admixture to propo-
fol. As the PKPD parameters were identical between the two
formulas the individual difference of the predicted plasma
propofol concentrations in the two study sessions gives im-
portant information on the intra-individual prediction error.
The ratio of the propofol concentrations with and without
EDTA was between 0.96 and 1.15 with some individuals
showing a negative, some a positive and others a fluctuating
ratio, suggesting a substantial intra-individual variation of
the PKs in the range of ≤30%.32 This is supported by previous
data by Hill and colleagues36 who found a 15.9% perform-
ance error of alfentanil despite individual tailoring of PK para-
meters. This means that the individual PK parameter set may
change from one study session to another, which would
appear as random effect in the modelling process. The pre-
diction error of a population is very unlikely better than the
prediction error in an individual subject.
Volume 1 and clearance 1 are the most important para-
meters to define the initial bolus and maintenance infusion.
By individual post hoc Bayesian corrections of these two
parameters according to one measurement of the plasma
alfentanil concentration, the prediction error of the indivi-
dualized parameters was improved in some patients but
not in others.37 The mean absolute performance error in
the population did therefore not change but its standard de-
viation decreased. Interestingly, adding more than one
measurement of the plasma concentration did not further
improve the performance error.
In the Maitre18 parameters compared with the Scott20
parameters, the volume of the central compartment (V1)
and the elimination clearance (Cl 1) are three times higher.
A TCI pump driven with the Maitre18 parameters will there-
fore infuse a higher amount of alfentanil in order to get a
given target plasma concentration. The Maitre25 parameters
also predict a faster decay of the plasma concentration after
the stop of infusion, which may be clinically irrelevant,
however. The difference in the amount infused is lower
with increasing age and higher in women compared with
men attributable to the gender and age sensitivity of the
Maitre parameters. A simulation of a TCI of 120 min with
a target plasma concentration of 200 ng ml21 in a
40-year-old man (70 kg, 170 cm) yielded a cumulative alfen-
tanil dose of 9 mg with the Scott and 14 mg with the Maitre
parameters. In a 40-year-old woman of the same height and
weight, the amount infused would be 14.8 mg (Fig. 5). Redu-
cing the target plasma concentration from 200 to 130 ng
ml21 in the Maitre driven pump would lower the cumulative
dose to 9 mg. The 50% decrement time after a 2 h infusion
would be 45 min according to Maitre and 47 min according
to Scott. An anaesthesia display or TCI will predict lower
plasma alfentanil concentrations with the Maitre parameters
compared with the Scott parameters, as illustrated in
Figure 1. By adjusting the target concentrations to clinical
effect the clinician can successfully handle such differences
between models.29
The prediction error as defined by Varvel30 (equation 1) and
used by many authors has been criticized3 because parameter
sets overpredicting the measured concentrations are
favoured. With a given measured plasma alfentanil concentra-
tion of 100 ng ml21 a predicted concentration of 80 ng ml21
(Cm2Cp¼+20 ng ml21¼underprediction, see equation 1)
yields an absolute PE of 25%. A predicted concentration of
120 ng ml21 (Cm2Cp¼220 ng ml21¼overprediction) yields
an absolute PE of 16.7%. Masui,3 therefore, proposed the loga-
rithmic accuracy and bias, respectively (equations 8 and 9),
which are not affected by the direction of the deviation
(overprediction vs underprediction). Although there are some
differences in the statistic pair-wise comparison between log
accuracy and MDAPE and log bias and MDPE, respectively,
the conclusions drawn from the different performance para-
meters are similar.
There are certainly some limitations in our study: the
number and timing of blood samples are not balanced in
the two data sets. It was not the intention of the two
studies from where the data were used, to evaluate or
even develop a new PK parameter set for alfentanil but
only to control potential prediction errors of the used
model. We cannot exclude that this may have affected the
precision of MDAPE and MDPE in the bolus data set.
Because the blood samples were obtained in the flat part
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Fig 5 Comparison of the infusion rate in a TCI driven by the Scott
and the Maitre parameters. A 120-min infusion of alfentanil at a
target plasma concentration of 200 ng ml21 was simulated for a
40-year-old person of 70 kg and 170 cm. The calculated infusion
rates, when using the Scott (weight adjusted) and the Maitre
parameters, are shown. The blue line represents the infusion
rate according to Scott, the red solid and dashed lines the infu-
sion rates according to Maitre (man and woman, respectively).
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of the concentration-time curve and not during the peaks the
performance error of the predicted plasma concentrations
are unlikely to be biased.
The two study groups did not differ in gender distribution,
but the patients of the bolus group were significantly older
and 50% were ASA physical status II (compared with 13%
in the infusion group). The reasons were obesity, hyperten-
sion, smoking of .20 pack years, diabetes, exercise
asthma and clinically insignificant liver disease. It is very un-
likely that these co-morbidities that were not associated with
clinical symptoms in normal daily life would have substan-
tially affected PKs of alfentanil.
The two groups also differed in the type of hypnotic drug
(propofol in the bolus group vs xenon or nitrous oxide plus
desflurane in the infusion group). It is not very likely
however, that the propofol effect on alfentanil PKs as
reported by Mertens28 was the dominating reason for the dif-
ference seen in some parameter sets because the perform-
ance of the Mertens parameters was substantially inferior
to the Scott parameters. Within Group I, there was no differ-
ence in the parameter sets’ performance between patients
receiving xenon and those receiving nitrous oxide plus
desflurane.
Conclusion
In healthy orthopaedic patients, the PK parameters by Scott
and Maitre were equally valid when alfentanil was given as
repeated boluses. When given as infusion, the Maitre para-
meters were less accurate and subject to a significant bias.
We cannot exclude that the difference between bolus and in-
fusion is partially because of the different hypnotics used.
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